AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$ELVN

Collins Helen Louise sold $252K of ELVN

Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $50.35 ($50.03–$51.48, $0.25M total) across 3 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Collins Helen Louise
Published Sep 21, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ELVN
Neutral
medium confidence
Mentioned
$ELVN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNNeutralLow
01

Why it matters

Insider sale of 5,000 shares at $50-$51 per share, total $251,754, via 10b5-1 plan.

02

Market read

Small insider sale; limited immediate market impact.

03

What to watch

Potential upcoming clinical data could offset sale impact.

Relevance 3/10Novelty 4/10Timing: filed Sep 21 2026

Background

Form 4 filing discloses insider transactions; standard regulatory disclosure.

Company-level read

Ticker impact

$ELVNNeutralMedium confidence
Context

C-suite insider sold ~250K shares via 10b5-1 plan, reducing holdings to 25,000 shares.

Expected impact

Possible slight downward pressure in near term.

Evidence & confidence

Sale size is modest relative to market cap and follows a pre-arranged plan, limiting actionable insight.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

Sale may be routine; could be ignored.

Key entities

  • Company
    Enliven Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ELVN.

  • Person
    Helen Louise Collins

    Chief Medical Officer of Enliven Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELVN insider trading history →

Related articles

OCT 8
$ELVNMedAI 8/10

Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment

Guggenheim reiterated a Buy rating and $78 price target for Enliven Therapeutics (ELVN) after FDA alignment on its Phase 3 study design for relcobatinib. The stock is down 10.5% this week but up 169% YTD. Multiple analysts have initiated coverage with positive ratings and price targets ranging from $70 to $78. The Phase 3 trial will enroll 450 patients and is set to start by year-end 2026.

investing.com2 min
OCT 6
$ELVNMedAI 8/10

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven Therapeutics (ELVN) reached FDA agreement on the Phase 3 trial design for relcobatinib (ELVN-001) in treating chronic myeloid leukemia. The ENABLE-2 trial will compare relcobatinib to second-generation TKIs, with a target enrollment of 450 patients. The company plans to initiate the trial by year-end 2026.

prnewswire.com2 min
OCT 1
$ELVNMed

Enliven Therapeutics stock initiated at Overweight by JPMorgan

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.

investing.com2 min